Societal CDMO Dividend

Dividend criteria checks 0/6

Societal CDMO hat in der Vergangenheit keine Dividende gezahlt.

Key information

n/a

Dividend yield

n/a

Payout ratio

Industry average yield	2.3%
Next dividend pay date	n/a
Ex dividend date	n/a
Dividend per share	n/a
Earnings per share	-US$0.13
Dividend yield forecast in 3Y	n/a

Recent dividend updates

No updates

Recent updates

Societal CDMO, Inc.'s (NASDAQ:SCTL) Price Is Right But Growth Is Lacking After Shares Rocket 38%

Feb 10

Is There An Opportunity With Societal CDMO, Inc.'s (NASDAQ:SCTL) 46% Undervaluation?

Feb 02

These 4 Measures Indicate That Societal CDMO (NASDAQ:SCTL) Is Using Debt Extensively

Apr 29

Is Recro Pharma (NASDAQ:REPH) A Risky Investment?

Jan 06

Recro Pharma jumps 15% on Q1 result estimates beat

May 07

Would Shareholders Who Purchased Recro Pharma's (NASDAQ:REPH) Stock Year Be Happy With The Share price Today?

Feb 15

Recro Pharma (REPH) Investor Presentation - Slideshow

Nov 22

Stability and Growth of Payments

Fetching dividends data

Stabile Dividende: Es liegen keine ausreichenden Daten vor, um festzustellen, ob die Dividende je Aktie von SCTL in der Vergangenheit stabil geblieben ist.

Wachsende Dividende: Unzureichende Daten, um festzustellen, ob die Dividendenzahlungen von SCTL gestiegen sind.

Dividend Yield vs Market

Societal CDMO Dividend Yield vs Market

How does SCTL dividend yield compare to the market?
Segment	Dividend Yield
Company (SCTL)	n/a
Market Bottom 25% (US)	1.5%
Market Top 25% (US)	4.7%
Industry Average (Pharmaceuticals)	2.3%
Analyst forecast in 3 Years (SCTL)	n/a

Bemerkenswerte Dividende: Es ist nicht möglich, die Dividendenrendite von SCTL im Vergleich zu den unteren 25 % der Dividendenzahler zu bewerten, da das Unternehmen keine aktuellen Ausschüttungen gemeldet hat.

Hohe Dividende: Es ist nicht möglich, die Dividendenrendite von SCTL im Vergleich zu den besten 25 % der Dividendenzahler zu bewerten, da das Unternehmen keine aktuellen Ausschüttungen gemeldet hat.

Earnings Payout to Shareholders

Abdeckung der Erträge: Unzureichende Daten zur Berechnung der Ausschüttungsquote von SCTL, um festzustellen, ob die Dividendenzahlungen durch die Gewinne gedeckt sind.

Cash Payout to Shareholders

Cashflow-Deckung: Es ist nicht möglich, die Nachhaltigkeit der Dividende zu berechnen, da SCTL keine Ausschüttungen gemeldet hat.

Discover strong dividend paying companies

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Societal CDMO Dividend

Dividend criteria checks 0/6

Key information

Recent dividend updates

Recent updates

Full year 2023 earnings: EPS and revenues exceed analyst expectations

CoreRx, Inc. entered into a definitive agreement to acquire Societal CDMO, Inc. (NasdaqCM:SCTL) from First Light Asset Management, LLC and Others for approximately $120 million.

New major risk - Share price stability

Now 29% overvalued after recent price rise

Societal CDMO, Inc.'s (NASDAQ:SCTL) Price Is Right But Growth Is Lacking After Shares Rocket 38%

Is There An Opportunity With Societal CDMO, Inc.'s (NASDAQ:SCTL) 46% Undervaluation?

Is Societal CDMO (NASDAQ:SCTL) Weighed On By Its Debt Load?

Price target decreased by 14% to US$1.86

High number of new directors

Nasdaq Grants Societal CDMO an Additional 180 Calendar Days to Regain Compliance with Minimum Bid Price Requirement

Societal CDMO, Inc. Resets Earnings Guidance for the Year 2023

Societal CDMO, Inc. to Report Q3, 2023 Results on Nov 08, 2023

Societal CDMO, Inc. Reduces its Workforce by 26 Positions Across All Aspects of the Business

High number of new directors

Price target decreased by 18% to US$2.30

Societal CDMO, Inc. has completed a Follow-on Equity Offering.

Societal Cdmo Announces Appointment of Matt Arens to Board of Directors

Consensus EPS estimates fall by 18%

New major risk - Shareholder dilution

Second quarter 2023 earnings: EPS misses analyst expectations

Societal CDMO, Inc. to Report Q2, 2023 Results on Aug 09, 2023

New minor risk - Share price stability

Does Societal CDMO (NASDAQ:SCTL) Have A Healthy Balance Sheet?

Societal CDMO Receives Deficiency Letter from Nasdaq Regarding Minimum Bid Price Requirement

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Societal CDMO, Inc. Reaffirms 2023 Financial Guidance

Societal CDMO, Inc. to Report Q1, 2023 Results on May 10, 2023

Forecast to breakeven in 2025

Price target decreased by 13% to US$3.64

Full year 2022 earnings: EPS misses analyst expectations

Price target increased by 19% to US$5.00

Consensus EPS estimates fall by 16%

Societal CDMO, Inc. has completed a Follow-on Equity Offering in the amount of $30.625911 million.

Societal CDMO, Inc. has completed a Follow-on Equity Offering in the amount of $30.625911 million.

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Societal CDMO, Inc. Provides Earnings Guidance for the Full Year 2022

Societal CDMO, Inc. to Report Q3, 2022 Results on Nov 09, 2022

Societal CDMO signs two CDMO service agreements

Societal CDMO, Inc. Appoints Elena Cant as Board of Directors

Societal stock soars 20% on signing 2 manufacturing contracts

Societal CDMO estimates to receive up to $50M on real estates' sales

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Societal CDMO, Inc. Provides Earnings Guidance for the Full Year Ending December 31, 2022

Societal CDMO, Inc. to Report Q2, 2022 Results on Aug 10, 2022

Societal CDMO, Lannett amend license and supply deal

Railroad Ranch Capital Engages in Discussions with Societal CDMO

Societal Cdmo Unveils 20/80 Second Source Technical Transfer Service Model, Offering Cost and Time Savings for Pharmaceutical Manufacturing

Consensus forecasts updated

Societal CDMO, Inc. Provides Earnings Guidance for the Year Ending December 31, 2022

Societal CDMO, Inc. to Report Q1, 2022 Results on May 11, 2022

These 4 Measures Indicate That Societal CDMO (NASDAQ:SCTL) Is Using Debt Extensively

Price target decreased to US$5.00

Societal CDMO, Inc., Annual General Meeting, May 18, 2022

Consensus forecasts updated

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Recro Pharma, Inc. Provides Earnings Guidance for the Year 2022

Recro Pharma, Inc. to Report Q4, 2021 Results on Mar 01, 2022

Is Recro Pharma (NASDAQ:REPH) A Risky Investment?

Third quarter 2021 earnings released: US$0.068 loss per share (vs US$0.09 loss in 3Q 2020)

Consensus forecasts updated

Consensus forecasts updated

Recro Pharma, Inc. (NasdaqCM:REPH) acquired IRISYS, LLC from EPS Americas, Corp., IriSys, Inc. and Continent Pharmaceuticals U.S., Inc. for $51.7 million.

Second quarter 2021 earnings released: EPS US$0.032 (vs US$0.26 loss in 2Q 2020)

Recro Pharma, Inc.(NasdaqCM:REPH) dropped from Russell 3000E Growth Index

Recro Pharma, Inc. Expands Capabilities for Growing Clinical Trial Services Offerings

Recro Pharma, Inc. has completed a Follow-on Equity Offering in the amount of $29.999999 million.

Consensus forecasts updated

First quarter 2021 earnings released: US$0.23 loss per share (vs US$0.33 loss in 1Q 2020)

Recro Pharma, Inc. Provides Earnings Guidance for the Year 2021

Recro Pharma jumps 15% on Q1 result estimates beat

Earnings beat expectations, revenue disappoints

Full year 2020 earnings released: US$1.16 loss per share (vs US$0.21 profit in FY 2019)

New 90-day high: US$5.04

Recro Pharma, Inc. to Report Q4, 2020 Results on Feb 26, 2021

Would Shareholders Who Purchased Recro Pharma's (NASDAQ:REPH) Stock Year Be Happy With The Share price Today?